FR2775003A1 - Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 - Google Patents
Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 Download PDFInfo
- Publication number
- FR2775003A1 FR2775003A1 FR9802025A FR9802025A FR2775003A1 FR 2775003 A1 FR2775003 A1 FR 2775003A1 FR 9802025 A FR9802025 A FR 9802025A FR 9802025 A FR9802025 A FR 9802025A FR 2775003 A1 FR2775003 A1 FR 2775003A1
- Authority
- FR
- France
- Prior art keywords
- expression
- nucleic acid
- polypeptide
- acid sequence
- stat1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 88
- 108010044012 STAT1 Transcription Factor Proteins 0.000 title claims abstract description 62
- 102000006381 STAT1 Transcription Factor Human genes 0.000 title claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 56
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 56
- 101000671637 Homo sapiens Upstream stimulatory factor 1 Proteins 0.000 title claims abstract description 52
- 102100040105 Upstream stimulatory factor 1 Human genes 0.000 title claims abstract description 50
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 230000003993 interaction Effects 0.000 title abstract description 6
- 108700002010 MHC class II transactivator Proteins 0.000 title description 23
- 229920001184 polypeptide Polymers 0.000 claims abstract description 55
- 230000027455 binding Effects 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000004913 activation Effects 0.000 claims abstract description 26
- 102000004127 Cytokines Human genes 0.000 claims abstract description 24
- 108090000695 Cytokines Proteins 0.000 claims abstract description 24
- 108091035710 E-box Proteins 0.000 claims abstract description 10
- 230000009467 reduction Effects 0.000 claims abstract description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 47
- 102000014150 Interferons Human genes 0.000 claims description 40
- 108010050904 Interferons Proteins 0.000 claims description 40
- 229940079322 interferon Drugs 0.000 claims description 40
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 27
- 238000005259 measurement Methods 0.000 claims description 20
- 230000006698 induction Effects 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 108700008625 Reporter Genes Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 102000018146 globin Human genes 0.000 claims description 3
- 108060003196 globin Proteins 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 6
- 239000012634 fragment Substances 0.000 abstract description 4
- 239000013598 vector Substances 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 39
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 30
- 238000001994 activation Methods 0.000 description 21
- 239000000523 sample Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108700005092 MHC Class II Genes Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000002079 cooperative effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150071002 Ciita gene Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 101000948324 Homo sapiens Protein CutA Proteins 0.000 description 1
- 101000837845 Homo sapiens Transcription factor E3 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000671649 Homo sapiens Upstream stimulatory factor 2 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101100382123 Mus musculus Ciita gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100202428 Neopyropia yezoensis atps gene Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100036046 Protein CutA Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100028507 Transcription factor E3 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100040103 Upstream stimulatory factor 2 Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9802025A FR2775003A1 (fr) | 1998-02-19 | 1998-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
| EP99903787A EP1068310B1 (fr) | 1998-02-19 | 1999-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
| DE69938450T DE69938450T2 (de) | 1998-02-19 | 1999-02-19 | Verfahren zum auffinden von verbindungen, die die bindung zwischen den transkriptionsfaktoren stat1 und usf1 hemmen |
| AU24312/99A AU2431299A (en) | 1998-02-19 | 1999-02-19 | Method for screening compounds capable of inhibiting fixing between the transcription factor of stat1 and the transcription factor of usf1 |
| JP2000532511A JP2002504325A (ja) | 1998-02-19 | 1999-02-19 | 転写因子ｓｔａｔ１と転写因子ｕｓｆ１の間の結合を阻害する能力をもつ化合物のスクリーニング方法 |
| PCT/FR1999/000376 WO1999042571A1 (fr) | 1998-02-19 | 1999-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
| US09/641,999 US6379894B1 (en) | 1998-02-19 | 2000-08-18 | Method for screening compounds capable of inhibiting binding between the transcription factor of STAT1 and the transcription factor of USF1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9802025A FR2775003A1 (fr) | 1998-02-19 | 1998-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2775003A1 true FR2775003A1 (fr) | 1999-08-20 |
Family
ID=9523151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9802025A Pending FR2775003A1 (fr) | 1998-02-19 | 1998-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6379894B1 (https=) |
| EP (1) | EP1068310B1 (https=) |
| JP (1) | JP2002504325A (https=) |
| AU (1) | AU2431299A (https=) |
| DE (1) | DE69938450T2 (https=) |
| FR (1) | FR2775003A1 (https=) |
| WO (1) | WO1999042571A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10148886A1 (de) | 2001-10-04 | 2003-04-30 | Avontec Gmbh | Inhibition von STAT-1 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995028492A1 (en) * | 1994-04-14 | 1995-10-26 | Ligand Pharmaceuticals Incorporated | Dna regulatory elements responsive to cytokines |
| WO1995028482A2 (en) * | 1994-04-14 | 1995-10-26 | Ligand Pharmaceuticals Incorporated | Dna spacer regulatory elements responsive to cytokines and methods for their use |
| WO1996015265A1 (en) * | 1994-11-10 | 1996-05-23 | The General Hospital Corporation | METHODS FOR MODULATING TRANSCRIPTION FROM THE AMYLOID β-PROTEIN PRECURSOR (APP) PROMOTER |
| EP0874049A1 (fr) * | 1997-04-22 | 1998-10-28 | Transgene S.A. | Sequences d'acide nucléique de genes CIITA |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976835A (en) * | 1992-03-19 | 1999-11-02 | The Rockefeller University | Nucleic acids encoding receptor recognition factor Stat1α and Stat1β, and methods of use thereof |
| DE69429608T2 (de) | 1993-08-26 | 2002-09-12 | Novimmune Sa, Genf/Geneve | MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen |
| US5463023A (en) * | 1993-10-22 | 1995-10-31 | Washington University | Composition for inhibition of intracellular transcription |
| US5814517A (en) * | 1994-04-14 | 1998-09-29 | Ligand Pharmaceuticals, Inc. | DNA spacer regulatory elements responsive to cytokines and methods for their use |
| US5707803A (en) * | 1994-04-14 | 1998-01-13 | Ligand Pharmaceuticals, Inc. | DNA regulatory elements responsive to cytokines and methods for their use |
| US5672473A (en) | 1994-08-24 | 1997-09-30 | President And Fellows Of Harvard College | Methods of identifying compounds useful for treating autoimmune diseases |
| US5716622A (en) * | 1995-01-06 | 1998-02-10 | The Rockefeller University | Functionally active regions of signal transducer and activators of transcription |
| US5821053A (en) * | 1995-02-10 | 1998-10-13 | Center For Blood Research, Inc. | LIL-Stat DNA binding sites and methods for identifying inhibitory binding agents |
| GB9513342D0 (en) * | 1995-06-30 | 1995-09-06 | Medical Res Council | Complexes |
| ZA97476B (en) * | 1996-01-22 | 1998-07-21 | Res Dev Foundation | Novel methods for the characterization of compounds which stimulate STF-1 expression in pancreatic islet cells. |
| US6207391B1 (en) * | 1998-03-31 | 2001-03-27 | Tularik Inc. | High-throughput screening assays for modulators of STAT4 and STAT6 activity |
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
-
1998
- 1998-02-19 FR FR9802025A patent/FR2775003A1/fr active Pending
-
1999
- 1999-02-19 AU AU24312/99A patent/AU2431299A/en not_active Abandoned
- 1999-02-19 DE DE69938450T patent/DE69938450T2/de not_active Expired - Fee Related
- 1999-02-19 JP JP2000532511A patent/JP2002504325A/ja active Pending
- 1999-02-19 WO PCT/FR1999/000376 patent/WO1999042571A1/fr not_active Ceased
- 1999-02-19 EP EP99903787A patent/EP1068310B1/fr not_active Expired - Lifetime
-
2000
- 2000-08-18 US US09/641,999 patent/US6379894B1/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995028492A1 (en) * | 1994-04-14 | 1995-10-26 | Ligand Pharmaceuticals Incorporated | Dna regulatory elements responsive to cytokines |
| WO1995028482A2 (en) * | 1994-04-14 | 1995-10-26 | Ligand Pharmaceuticals Incorporated | Dna spacer regulatory elements responsive to cytokines and methods for their use |
| WO1996015265A1 (en) * | 1994-11-10 | 1996-05-23 | The General Hospital Corporation | METHODS FOR MODULATING TRANSCRIPTION FROM THE AMYLOID β-PROTEIN PRECURSOR (APP) PROMOTER |
| EP0874049A1 (fr) * | 1997-04-22 | 1998-10-28 | Transgene S.A. | Sequences d'acide nucléique de genes CIITA |
Non-Patent Citations (4)
Also Published As
| Publication number | Publication date |
|---|---|
| EP1068310B1 (fr) | 2008-04-02 |
| WO1999042571A1 (fr) | 1999-08-26 |
| DE69938450T2 (de) | 2009-05-07 |
| US6379894B1 (en) | 2002-04-30 |
| JP2002504325A (ja) | 2002-02-12 |
| EP1068310A1 (fr) | 2001-01-17 |
| DE69938450D1 (de) | 2008-05-15 |
| WO1999042571A8 (fr) | 1999-11-18 |
| AU2431299A (en) | 1999-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jing et al. | Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks | |
| Corthesy et al. | Purification by DNA affinity chromatography of two polypeptides that contact the NF-AT DNA binding site in the interleukin 2 promoter. | |
| Shama et al. | Overexpression of initiation factor eIF-4E does not relieve the translational repression of ribosomal protein mRNAs in quiescent cells | |
| Xi et al. | Interplay between RORγt, Egr3, and E proteins controls proliferation in response to pre-TCR signals | |
| Durand et al. | RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency | |
| Grohmann et al. | Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1) | |
| Wiersma et al. | Structural and functional analysis of J chain-deficient IgM | |
| Nguyen et al. | Tryptophan missense mutation in the ligand‐binding domain of the vitamin D receptor causes severe resistance to 1, 25‐dihydroxyvitamin D | |
| Nicholls et al. | UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation | |
| Satoh et al. | The constitutive and inducible expression of Nurr1, a key regulator of dopaminergic neuronal differentiation, in human neural and non‐neural cell lines | |
| EP0877758A2 (fr) | PROTEINE PURIFIEE SR-p70 | |
| FR2759701A1 (fr) | Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques | |
| EP0874049B1 (fr) | Séquences d'acide nucléique de genes CIITA | |
| CA2461692A1 (fr) | Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire | |
| Citterio et al. | Expression analysis of the human adducin gene family and evidence of ADD2 β4 multiple splicing variants | |
| FR2775003A1 (fr) | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 | |
| WO2001004299A1 (en) | AMYLOID β PROTEIN AGGLUTINATION CONTROLLING FACTOR | |
| Wrammert et al. | Identification of a novel thioredoxin‐related protein, PC‐TRP, which is preferentially expressed in plasma cells | |
| Reim et al. | The RRM protein NonA from Drosophila forms a complex with the RRM proteins Hrb87F and S5 and the Zn finger protein PEP on hnRNA | |
| Howard et al. | Expression of the synaptotagmin I gene is enhanced by binding of the pituitary-specific transcription factor, POU1F1 | |
| van Eggermond et al. | Transcriptional silencing of RFXAP in MHC class II-deficiency | |
| WO2004080272A2 (fr) | Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal | |
| EP1311708B1 (fr) | Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse au recepteur ror du gene ikappabalpha | |
| Anant et al. | Apobec-1 transcription in rat colon cancer: decreased apobec-1 protein production through alterations in polysome distribution and mRNA translation associated with upstream AUGs | |
| King | Cloning the 5′ flanking region of neuron-specificHel-N1: evidence for positive regulatory elements governing cell-specific transcription |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property |